Details for Patent: 8,329,668

Title:	Antisense antiviral compound and method for treating picornavirus infection
Abstract:	The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and/or Rhinovirus infection in a mammal. The antisense antiviral compounds are substantially uncharged, including partially positively charged, morpholino oligonucleotides have a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with viral RNA sequences within a 32 nucleotide region of the viral 5' untranslated region identified by SEQ ID NO:4.
Inventor(s):	Stein; David A. (Corvallis, OR), Rijnbrand; Cornelis A. (Poway, CA), Iversen; Patrick L. (Corvallis, OR), Weller; Dwight D. (Corvallis, OR)
Assignee:	AVI Biopharma, Inc. (Corvallis, OR)
Filing Date:	Sep 08, 2006
Application Number:	11/518,058
Claims:	1. A method of treating an Enterovirus or Rhinovirus infection in a mammalian subject, comprising: administering to the mammalian subject, a therapeutically effective amount of an antisense conjugate comprising: an antisense oligonucleotide composed of between 20 and 40 morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, and having a targeting sequence of at least 20 contiguous bases that are complementary to SEQ ID NO:4, and an arginine-rich carrier peptide conjugated to the antisense oligonucleotide, wherein the carrier peptide has the sequence of SEQ ID NO:16. 2. The method of claim 1, wherein the antisense conjugate forms a heteroduplex with at least 20 contiguous bases of SEQ ID NO: 4, wherein the heteroduplex has a Tm of dissociation of at least 45.degree. C. 3. The method of claim 1, wherein the intersubunit linkages are uncharged. 4. The method of claim 1, wherein at least 2 and no more than half of the total number of intersubunit linkages of the antisense oligonucleotide are positively charged at physiological pH. 5. The method of claim 1, wherein the morpholino subunits are joined by intersubunit linkages in accordance with the structure: ##STR00003## wherein Y.sub.1.dbd.O, Z.dbd.O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl; alkoxy; thioalkoxy; 1-piperazine; or --NR.sub.2, wherein each R is independently a hydrogen or methyl. 6. The method of claim 1, wherein the antisense oligonucleotide comprises at least 20 contiguous bases contained in SEQ ID NO:6. 7. The method of claim 6, wherein the antisense oligonucleotide sequence is selected from the group consisting of SEQ ID NOS:7, 8, 12 and 13. 8. The method of claim 1, further comprising administering an anti-viral composition to the mammalian subject. 9. The method of claim 1, wherein said administering is effective to reduce cardiopathology in a mammal infected with coxsackievirus B3. 10. The method of claim 1, wherein at least 2 and no more than half of the total number of intersubunit linkages of the antisense oligonucleotide contain a 1-piperazino group.